Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
SGHT vs PMI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PMI Captures Overall Composite Edge (48.4 HOLD vs 34.0 SELL), While SGHT Leads 4–1 on Growth & Valuation Pillars
PMI Overall Winner
6-Pillar Tally: SGHT 4 – 1 PMI (1 Tie)
Matrix Metrics: SGHT 4 – 5 PMI
As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Sight Sciences, Inc. (SGHT) on higher Unified Composite conviction (48.4/100 HOLD vs. 34.0/100 SELL) after splitting the core matrix 5–4 (led by Valuation Multiples), while SGHT wins 4–1 across the 6-pillar growth and valuation breakdown. SGHT trades at $10.62 (N/M Forward P/E, -20.2% operating margin) versus PMI at $6.30 (N/M Forward P/E, -248.1% operating margin).
- Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. SGHT 34.0/100 SELL) and 54.06β · 134% Vol risk profile, whereas SGHT leads top-line expansion (+25.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SGHT vs PMI
SGHT
Sight Sciences, Inc. Common Stock
$10.62
-1.39% 1D
Market Cap
$598.6M
TTM Revenue
$88M
Forward P/E
N/M
Beta / 30D Vol
1.06β · 46% Vol
Unified Composite Score
34.0
SELL
Tech 50.0
Fund 39.0
Flow 70.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
PMI
Head-to-Head Winner
Picard Medical, Inc.
$6.30
-2.17% 1D
Market Cap
$17.1M
TTM Revenue
$6.3M
Forward P/E
N/M
Beta / 30D Vol
54.06β · 134% Vol
Unified Composite Score
48.4
HOLD
Tech 39.0
Fund 45.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (SGHT 4 – 1 PMI)
1. Valuation Multiples
PMI
Forward P/E
N/M
N/M
Trailing P/E
N/M
2.9x
PEG Ratio
N/M
N/M
EV / Revenue
6.4x
3.2x
2. Growth & Scale
SGHT
Revenue Growth (YoY)
+25.2%
+38.6%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$88M
$6.3M
Market Cap
$598.6M
$17.1M
3. Profitability & Quality
SGHT
Gross Margin
87.7%
18.6%
Operating Margin
-20.2%
-248.1%
Net Profit Margin
-32.1%
0.0%
Return on Equity (ROE)
-50.1%
0.0%
4. Balance Sheet & Cash Flow
SGHT
Cash Generation (TTM)
-$17M
-$17M
Cash Flow Margin
-19.1%
N/A
Net Cash / Leverage
$35M Net Cash
$3.2M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SGHT
Options Structure Phase
BREAKOUT
UNCLASSIFIED
Current IV / %ile
78.7% (8th %ile)
N/A (N/A)
Put/Call OI Skew
0.01x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SGHT (4) vs PMI (5)| Institutional Metric | SGHT | PMI | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $598.6M | $17.1M | SGHT | |
| Trailing P/E Ratio | N/M | 2.9x | PMI | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +25.2% | +38.6% | PMI | |
| Operating Margin (TTM) | -20.2% | -248.1% | SGHT | |
| Net Profit Margin | -32.1% | 0.0% | PMI | |
| Return on Equity (ROE) | -50.1% | 0.0% | PMI | |
| 52-Week Range Position | 88% ($3–$12) | 34% ($0–$18) | SGHT | |
| Beta / 30D Volatility | 1.06β · 46% Vol | 54.06β · 134% Vol | SGHT | |
| Unified Institutional Score | 34.0 / 100 (SELL) | 48.4 / 100 (HOLD) | PMI | |
| Trailing 12M Revenue (USD) | $88M | $6.3M | Scale | |
| Gross Profit Margin (TTM) | 87.7% | 18.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 6.4x EV/Rev | N/M PEG · 3.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$17M ($35M Net Cash) | -$17M ($3.2M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SGHT +56.65 pp
3M Horizon
PMI +67.69 pp
6M Horizon
PMI +3323.91 pp
1Y Horizon
PMI +99.29 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SGHT Revenue | PMI Revenue | SGHT Op. Margin | PMI Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | $30M | N/A | -116.5% | N/A | SGHT |
| FY2021 | $50M | N/A | -105.2% | N/A | SGHT |
| FY2022 | $70M | N/A | -117.7% | N/A | SGHT |
| FY2023 | $80M | N/A | -70.7% | N/A | SGHT |
| FY2024 | $80M | $0M | -63.3% | -312.3% | SGHT |
| FY2025 | $80M | $0M | -48.0% | -268.4% | SGHT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SGHT
BREAKOUT
Current IV
78.7%
IV Percentile
8th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact SGHT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PMI
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SGHT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PMI Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SGHT vs PMI Key Questions & Quantitative Answers
As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Sight Sciences, Inc. (SGHT) on higher Unified Composite conviction (48.4/100 HOLD vs. 34.0/100 SELL) after splitting the core matrix 5–4 (led by Valuation Multiples), while SGHT wins 4–1 across the 6-pillar growth and valuation breakdown. SGHT trades at $10.62 (N/M Forward P/E, -20.2% operating margin) versus PMI at $6.30 (N/M Forward P/E, -248.1% operating margin). Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. SGHT 34.0/100 SELL) and 54.06β · 134% Vol risk profile, whereas SGHT leads top-line expansion (+25.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
SGHT leads the Growth & Scale pillar: SGHT posts +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), SGHT cumulative revenue shifted +166.7% while PMI shifted N/A. In operating R&D and SG&A reinvestment, SGHT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.
PMI screens cheaper on headline valuation multiples. SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-19.1% FCF margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGHT (-50.1% ROE) versus PMI (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.06β · 46% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PMI vs SGHT · Reverse Pair
SGHT vs CTKB
· Sector Peer
SGHT vs TMCI
· Sector Peer
SGHT vs RXST
· Sector Peer
PMI vs RDN
· Sector Peer
PMI vs MTG
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem